CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease

By Reuters News

Nov 11 (Reuters) - Amgen Inc AMGN.O:

  • AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

  • AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

  • AMGEN - GLOBAL PHASE 3 TRIAL SHOWS CLINICALLY MEANINGFUL IMPROVEMENTS IN SJÖGREN'S DISEASE

  • AMGEN - DAZODALIBEP REGIMENS MEET PRIMARY ENDPOINT AT WEEK 48 WITH SIGNIFICANT DISEASE ACTIVITY REDUCTION

  • AMGEN - 1,500 MG REGIMEN SHOWS 5.6-POINT ESSDAI REDUCTION VERSUS 3.8 FOR PLACEBO; ADJUSTED P<0.001

  • AMGEN - SERIOUS ADVERSE EVENTS AND DISCONTINUATIONS BALANCED ACROSS ALL TREATMENT GROUPS

  • AMGEN - DAZODALIBEP PATIENTS SHOW GREATER INCREASES IN STIMULATED SALIVARY FLOW VERSUS PLACEBO

  • AMGEN - NO IMBALANCE IN THROMBOEMBOLIC EVENTS OR INFECTIONS; MALIGNANCY RATES LOW AND COMPARABLE

Further company coverage: AMGN.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.